Following the FDA approval of rilzabrutinib (Wayrilz; Sanofi) for immune thrombocytopenia (ITP), a rare autoimmune disorder, David Kuter, MD, DPhil, highlights the most pressing a ...

Immune thrombocytopenia, previously known as idiopathic thrombocytopenic purpura (ITP), causes you to have a low platelet count. This may result in excessive bleeding inside and outside your body.

Medically reviewed by Gagandeep Brar, MD Key Takeaways ITP does not increase the risk of getting or having severe ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Immune thrombocytopenia (ITP) doesn’t have a cure and can be unpredictable. There are two main types of ITP, acute and chronic. The acute type usually lasts six months or less. It’s more common in ...

Immune thrombocytopenia (ITP) is a rare blood disorder in which the immune system mistakenly attacks and destroys platelets. Platelets are small blood cells that play a critical role in helping your ...

Idiopathic thrombocytopenic purpura (ITP), also known as primary immune thrombocytopenic purpura and autoimmune thrombocytopenic purpura, is defined as isolated thrombocytopenia with normal bone ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Administration of high-dose IVIg rapidly increases platelet numbers in individuals with the platelet autoimmune disease ITP. Although also of benefit in other autoimmune disorders, including ...

Immune thrombocytopenia (ITP) occurs when the immune system attacks and destroys healthy platelets. A person who has ITP is more likely to bruise or bleed. Thrombocytopenia means a person does not ...